Celaid Therapeutics is pleased to announce that Nobuchika Yamamoto, Principal Scientist, will present the Company's latest research findings at the European Hematology Association (EHA) 2026 Congress, to be held in Stockholm, Sweden, from June 11 to 14, 2026.
＜Presentation Details＞
Conference
European Hematology Association (EHA) 2026 Congress
Dates
June 11–14, 2026
Location
Stockholm, Sweden
Presentation Format
Poster Presentation
Abstract Number
PF1112
Title
Epigenetic Modulation Enables Expansion of Functional Human HSPCs in a Chemically Defined System for Cell and Gene Clinical Applications
Through continued innovation in cell engineering and regenerative medicine, Celaid Therapeutics remains committed to advancing next-generation therapies that address significant unmet medical needs in hematological and other serious diseases.
